Edgar Filing: Zakrzewski Joseph S - Form 4

Zakrzewski Josep Form 4	oh S									
October 02, 2018										
FORM 4		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	a-------------			~~~	~~~~~~~~~		PPROVAL	
	UNITED	STATES		RITIES A shington			COMMISSIO	N OMB Number:	3235-0287	
Check this box if no longer subject to Section 16. Form 4 or	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES								January 31, 2005 average irs per	
Form 5 obligations may continue. See Instruction 1(b).	Section 17(a) of the H	Public U	tility Hol	ding Cor		nge Act of 1934, of 1935 or Section 940	response on	. 0.5	
(Print or Type Respo	nses)									
1. Name and Address of Reporting Person <u>*</u> Zakrzewski Joseph S			Symbol	er Name an RIN CORI		Trading K [AMRN	5. Relationship of Reporting Person(s) to Issuer[] (Check all applicable)			
(Last)	(First) (I	Middle)	3. Date of Earliest Transaction (C							
C/O AMARIN PHARMA, INC., 1430 ROUTE 206			(Month/Day/Year) 05/14/2018				X_ Director 10% Owner Officer (give title Other (specify below) below)			
(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)			1	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting						
BEDMINSTER,	NJ 07921						Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)2. Transaction Data (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5)		Securities Beneficially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	(A)or(D) Price	Transaction(s) (Instr. 3 and 4)			
Reminder: Report or	a separate line	for each cla	ass of sec	urities bene	ficially own	ned directly	or indirectly.			
					inforn requir	nation cont ed to response ays a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: Zakrzewski Joseph S - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 3		Acquired (or Dispose (D) (Instr. 3, 4 and 5)	ed of				
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 3.21	05/14/2018		A		46,973		<u>(1)</u>	05/14/2028	Ordinary Shares (2)	46,973
Restricted Stock Units	\$ 0 <u>(3)</u>	05/14/2018		А		31,153		(4)	(5)	Ordinary Shares (2)	31,153

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Zakrzewski Joseph S C/O AMARIN PHARMA, INC. 1430 ROUTE 206 BEDMINSTER, NJ 07921	Х						
Signatures							
/s/ Michael W. Kalb, by power of attorney		10/02/2	018				

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On May 14, 2018, the Reporting Person was granted an option to purchase 46,973 Ordinary Shares under the Amarin Corporation plc
 (1) 2011 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of May 14, 2018 or (ii) the Issuer's annual general meeting of shareholders in 2019.

- (2) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer.

On May 14, 2018, the Reporting Person was granted 31,153 RSUs under the Plan. The RSUs vest in equal annual installments over a

- (4) three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of May 14, 2018 or (ii) the Issuer's annual general meeting of shareholders in such year.
- (5) Not applicable.

Remarks:

These grants are made in accordance with the Issuer's previously disclosed non-employee director compensation program. In t

Reporting Owners

Edgar Filing: Zakrzewski Joseph S - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.